Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: Initial experience

Journal of Neuro-Oncology

Volumn 95, Issue 2, 2009, Pages 185-197

  Grahn, Amy Y ^a   Bankiewicz, Krystof S ^c   Dugich Djordjevic, Millicent ^b   Bringas, John R ^c   Hadaczek, Piotr ^c   Johnson, Greg A ^a   Eastman, Simon ^d   Luz, Matthias ^a  

^a MedGenesis Therapeutix Inc   (Canada)

^b Neurocore   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Northern Lipids Inc   (Canada)

Author keywords

Brain tumor; Convection enhanced delivery; Gadodiamide; Liposome; Topotecan

Indexed keywords

GADODIAMIDE; LIPOSOME; NANOPARTICLE; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CONVECTION ENHANCED DELIVERY; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TISSUE LEVEL; GLIOMA; HUMAN; HUMAN CELL; IC 50; LOW DRUG DOSE; MALE; NONHUMAN; RAT; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL SURVIVAL; CONTRAST MEDIA; CONVECTION; DRUG DELIVERY SYSTEMS; GADOLINIUM DTPA; GLIOBLASTOMA; HUMANS; LIPOSOMES; MALE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL RATE; TISSUE DISTRIBUTION; TOPOTECAN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350026365     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9917-1     Document Type: Article

References (40)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
2. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578
3. Rapisarda A, Zalek J, Hollingshead M et al (2004) Schedule-dependent inhibition of hypoxia-inducible factor-1α protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64:6845-6848. doi: 10.1158/0008-5472.CAN-04-2116
4. Marchesini R, Colombo A, Caserini C et al (1996) Interaction of ionizing radiation with topotecan in two human tumor cell lines. Int J Cancer 66:342-346. doi: 10.1002/ (SICI)1097-0215(19960503)66:3<342::AID-IJC13>3.0.CO;2-D
5. Schmidt F, Rieger J, Wischhusen J, Naumann U, Weller M (2001) Glioma cell sensitivity to topotecan: The role of p53 and topotecan-induced DNA damage. Eur J Pharmacol 412:21-25. doi: 10.1016/S0014-2999(00)00923-7
6. Mainwaring MG, Gomez SP, Marsh RD, Chen S (2001) Sequential temozolomide followed by topotecan in the treatment of glioblastoma multiforme. Proc Am Soc Clin Oncol 20:245 (abstract)
7. Fisher BJ, Scott C, Macdonald DR, Coughlin C, Curran WJ (2001) Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507. J Clin Oncol 19:1111-1117
8. Fisher B, Won M, MacDonald D, Johnson DW, Roa W (2002) Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: Results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys 53:980-986. doi: 10.1016/S0360-3016(02)02817-1
9. Grabenbauer GG, Anders K, Fietkau RJ et al (2002) Prolonged infusional topotecan and accelerated hyperfractionated 3d-conformal radiation in patients with newly diagnosed glioblastoma-a phase I study. J Neurooncol 60:269-275. doi: 10.1023/A:1021100413142
10. Lesimple T, Hassel MB, Gedouin D et al (2003) Phase I study of topotecan in combination with concurrent radiotherapy in adults with glioblastoma. J Neurooncol 65:141-148. doi: 10.1023/B:NEON.0000003647.66788.3b
11. Gross MW, Altscher R, Brandtner M et al (2005) Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults. Clin Neurol Neurosurg 107:207-213. doi: 10.1016/j.clineuro.2004.07.016
12. Pipas JM, Meyer LP, Rhodes CH, Cromwell LD, McDonnell CE, Kingman LS, Rigas JR, Fadul CE (2005) A phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neurooncol 71:301-305. doi: 10.1007/s11060-004-2026-2
13. Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H (1995) Intratumoral chemotherapy. Neurosurgery 37:1129-1145. doi: 10.1097/ 00006123-199512000-00013
14. Lieberman DM, Laske DW, Morrison PF et al (1995) Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82:1021-1029
15. Croteau D, Walbridge S, Morrison PF et al (2005) Real-time in vivo imaging of the convective distribution of a low-molecular-weight tracer. J Neurosurg 102:90-97
16. Lonser RR, Walbridge S, Garmestani K et al (2002) Successful and safe perfusion of the primate brainstem: In vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 97:905-913
17. Bobo RH, Laske DW, Akbasak A et al (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91:2076-2080. doi: 10.1073/pnas.91.6.2076
18. Morrison PF, Laske DW, Bobo H et al (1994) High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol 266:R292-R305
19. Vogelbaum MA (2007) Convection enhanced delivery for treating brain tumors and selected neurological disorders: Symposium review. J Neurooncol 83:97-109. doi: 10.1007/s11060-006-9308-9
20. Moog R, Burger AM, Brandl M et al (2002) Change in pharmacokinetics and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer Chemother Pharmacol 49:356-366. doi: 10.1007/s00280-002-0428-4
21. Saito R, Krauze MT, Noble CO et al (2006) Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro-oncology 8:205-214. doi: 10.1215/15228517-2006-001
22. Noble CO, Krauze MT, Drummond DC et al (2006) Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res 66:2801-2806. doi: 10.1158/ 0008-5472.CAN-05-3535
23. Woodle MC, Lasic DD (1992) Sterically stabilized liposomes. Biochim Biophys Acta 1113:171-199
24. Ishida T, Kiwada H (2008) Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 354:56-62. doi: 10.1016/j.ijpharm.2007.11.005
25. Szebeni J, Baranyi L, Savay S et al (2002) Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res 12:165-172. doi: 10.1081/LPR-120004790
26. Szebeni J (2005) Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity. Toxicology 216:106-121. doi: 10.1016/j.tox.2005.07.023
27. Saito R, Krauze MT, Noble CO et al (2006) Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: Implications for local drug delivery. J Neurosci Methods 154:225-232. doi: 10.1016/j.jneumeth.2005.12.027
28. Mamot C, Nguyen JB, Pourdehnad M et al (2004) Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol 68:1-9. doi: 10.1023/ B:NEON.0000024743.56415.4b
29. Saito R, Bringas JR, McKnight TR et al (2004) Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res 64:2572-2579. doi: 10.1158/0008-5472.CAN-03-3631
30. Krauze MT, Forsayeth J, Park JW, Bankiewicz KS (2006) Real-time imaging and quantification of brain delivery of liposomes. Pharm Res 23:2493-2504. doi: 10.1007/s11095-006-9103-5
31. Krauze MT, Vandenberg SR, Yamashita Y et al (2008) Safety of real-time convection-enhanced delivery of liposomes to primate brain: A long-term retrospective. Exp Neurol 210:638-644. doi: 10.1016/ j.expneurol.2007.12.015
32. Murad GJ, Walbridge S, Morrison PF et al (2006) Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to pseudomonas exotoxin. Clin Cancer Res 12:3145-3151. doi: 10.1158/ 1078-0432.CCR-05-2583
33. Broaddus WC (2007) Convection enhanced delivery 3rd international symposium, trial update: TransMID. Available at http://cms.clevelandclinic.org/neuroscience/documents/ 1340%20Broaddus%20Update%20on%20TransMID%20Trial.pdf. Accessed 11 Feb 2008
34. Kunwar S, Westphal M, Medhorn M et al (2007) Results from PRECISE: A randomized phase 3 study in patients with first recurrent glioblastoma multiforme (GBM) comparing cintredekin besudotox (CB) administered via convection-enhanced delivery (CED) with Gliadel Wafers (GW). Neuro-oncology 9:531 (abstract)
35. Sampson JH, Raghavan R, Brady ML et al (2007) Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro-oncology 9:343-353. doi: 10.1215/15228517-2007-007
36. Krauze MT, Noble CO, Kawaguchi T et al (2007) Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro-oncology 9:393-403. doi: 10.1215/15228517-2007-019
37. Nakashio A, Fujita N, Tsuruo T (2002) Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. Int J Cancer 98:36-41. doi: 10.1002/ ijc.10166
38. Saito R, Krauze MT, Bringas JR et al (2005) Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol 196:381-389. doi: 10.1016/ j.expneurol.2005.08.016
39. Dickensen PJ, LeCouteur RA, Higgins RJ et al (2008) Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging. J Neurosurg 108:989-998. doi: 10.3171/JNS/2008/108/5/0989
40. Yamashita Y, Krauze MT, Kawaguchi T et al (2007) Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro-oncology 9:20-28. doi: 10.1215/15228517-2006-016